6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?

作者信息

Derijks Luc J J, Gilissen Lennard P L, de Boer Nanne K H, Mulder Chris J J

出版信息

J Hepatol. 2006 Apr;44(4):821-2. doi: 10.1016/j.jhep.2005.11.049. Epub 2006 Jan 24.

DOI:10.1016/j.jhep.2005.11.049

PMID:16487623

Abstract

摘要

相似文献

6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?

J Hepatol. 2006 Apr;44(4):821-2. doi: 10.1016/j.jhep.2005.11.049. Epub 2006 Jan 24.

[Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].

Dtsch Med Wochenschr. 2003 Feb 21;128(8):378-85. doi: 10.1055/s-2003-37378.

Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.

J Crohns Colitis. 2012 Feb;6(1):95-101. doi: 10.1016/j.crohns.2011.07.009.

Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?

Dig Liver Dis. 2007 Feb;39(2):156-9. doi: 10.1016/j.dld.2006.10.007. Epub 2006 Dec 26.

6TG: when less is more than you bargained for.

Inflamm Bowel Dis. 2003 Nov;9(6):394-5. doi: 10.1097/00054725-200311000-00010.

Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.

Am J Gastroenterol. 2007 Jul;102(7):1518-27. doi: 10.1111/j.1572-0241.2007.01187.x. Epub 2007 Mar 27.

[Therapeutic drug monitoring of 6-thioguanine nucleotides in inflammatory bowel disease: interest and limits].

Therapie. 2010 May-Jun;65(3):177-86. doi: 10.2515/therapie/2010030. Epub 2010 Aug 11.

Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.

J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181.

Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.

Aliment Pharmacol Ther. 2007 Apr 15;25(8):941-7. doi: 10.1111/j.1365-2036.2007.03278.x.

6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.

Eur J Gastroenterol Hepatol. 2003 Jan;15(1):63-7. doi: 10.1097/00042737-200301000-00011.

引用本文的文献

Uphill battle: Innovation of thiopurine therapy in global inflammatory bowel disease care.

Indian J Gastroenterol. 2024 Feb;43(1):36-47. doi: 10.1007/s12664-024-01529-x. Epub 2024 Feb 21.

Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency.

Metabolites. 2023 Oct 6;13(10):1054. doi: 10.3390/metabo13101054.

The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.

Inflamm Bowel Dis. 2024 Sep 3;30(9):1492-1499. doi: 10.1093/ibd/izad197.

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Clin Pharmacokinet. 2018 Sep;57(9):1075-1106. doi: 10.1007/s40262-018-0639-4.

Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):5-20. doi: 10.4292/wjgpt.v7.i1.5.

Use of thiopurines in inflammatory bowel disease.

World J Gastroenterol. 2013 Feb 21;19(7):1040-8. doi: 10.3748/wjg.v19.i7.1040.

Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis.

BMC Gastroenterol. 2011 May 5;11:47. doi: 10.1186/1471-230X-11-47.

A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.

Wien Klin Wochenschr. 2007;119(17-18):519-26. doi: 10.1007/s00508-007-0841-0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验